Literature DB >> 29605498

Delayed versus standard assessment for excision surgery in patients with Buruli ulcer in Benin: a randomised controlled trial.

Akpeedje C Wadagni1, Yves T Barogui2, Roch C Johnson3, Ghislain E Sopoh2, Dissou Affolabi4, Tjip S van der Werf5, Janine de Zeeuw5, Johanneke Kleinnijenhuis5, Ymkje Stienstra6.   

Abstract

BACKGROUND: Surgical intervention was once the mainstay of treatment for Buruli ulcer disease, a neglected tropical disease caused by Mycobacterium ulcerans. Since the introduction of streptomycin and rifampicin for 8 weeks as standard care, surgery has persisted as an adjunct therapy, but its role is uncertain. We investigated the effect of delaying the decision to operate to 14 weeks on rates of healing without surgery.
METHODS: In this randomised controlled trial, we enrolled patients aged 3 years or older with confirmed disease at one hospital in Lalo, Benin. Patients were randomly assigned (1:1) to groups assessing the need for excision surgery 8 weeks (standard care) or 14 weeks after initiation of antimicrobial treatment. The primary endpoint was the number of patients healed without the need for surgery (not including skin grafting), assessed in all patients in follow-up at 50 weeks (or last observation for those healed for >10 weeks). A doctor masked to treatment assignment checked the indications for surgery according to predefined criteria. This study is registered with ClinicalTrials.gov, number NCT01432925.
FINDINGS: Between July 1, 2011, and Jan 15, 2015, 119 patients were enrolled, with two patients per group lost to follow-up. 55 (96%) of 57 participants in the delayed-decision group and 52 (90%) of 58 participants in the standard-care group had healed lesions 1 year after start of antimicrobial treatment (relative risk [RR] 1·08, 95% CI 0·97-1·19). 37 (67%) of 55 patients in the delayed-decision group had their lesions healed without surgical intervention, as did 25 (48%) of 52 in the standard-care group (RR 1·40, 95% CI 1·00-1·96). The time to heal and residual functional limitations did not differ between the two groups (median time to heal 21 weeks [IQR 10-27] in the delayed-decision group and 21 weeks [10-39] in the standard-care group; functional limitations in six [11%] of 57 and three [5%] of 58 patients; p=0·32). Postponing the decision to operate resulted in reduced median duration of hospitalisation (5 days [IQR 0-187] vs 131 days [0-224]; p=0·024) and wound care (153 days [IQR 56-224] vs 182 days [94-307]; p=0·036).
INTERPRETATION: In our study, patients treated for Buruli ulcer benefited from delaying the decision to operate. Even large ulcers can heal with antibiotics alone, without delaying healing rate and without an increase in residual functional limitations. FUNDING: NWO-VENI grant 241500, BUG Foundation, and UBS OPTIMUS.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29605498     DOI: 10.1016/S1473-3099(18)30160-9

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  11 in total

1.  Vaccine-Specific Immune Responses against Mycobacterium ulcerans Infection in a Low-Dose Murine Challenge Model.

Authors:  Brendon Y Chua; Timothy P Stinear; Kirstie M Mangas; Andrew H Buultjens; Jessica L Porter; Sarah L Baines; Estelle Marion; Laurent Marsollier; Nicholas J Tobias; Sacha J Pidot; Kylie M Quinn; David J Price; Katherine Kedzierska; Weiguang Zeng; David C Jackson
Journal:  Infect Immun       Date:  2020-02-20       Impact factor: 3.441

2.  In Vivo Imaging of Bioluminescent Mycobacterium ulcerans: A Tool to Refine the Murine Buruli Ulcer Tail Model.

Authors:  Till F Omansen; Renee A Marcsisin; Brendon Y Chua; Weiguang Zeng; David C Jackson; Jessica L Porter; Ymkje Stienstra; Tjip S van der Werf; Timothy P Stinear
Journal:  Am J Trop Med Hyg       Date:  2019-12       Impact factor: 2.345

3.  Comparison of 8 weeks standard treatment (rifampicin plus clarithromycin) vs. 4 weeks standard plus amoxicillin/clavulanate treatment [RC8 vs. RCA4] to shorten Buruli ulcer disease therapy (the BLMs4BU trial): study protocol for a randomized controlled multi-centre trial in Benin.

Authors:  Roch Christian Johnson; Emma Sáez-López; Esaï Sèdjro Anagonou; Godwin Gérard Kpoton; Adjimon Gilbert Ayelo; Ronald Sètondji Gnimavo; Franck Zinsou Mignanwande; Jean-Gabin Houezo; Ghislain Emmanuel Sopoh; Juliet Addo; Lindsay Orford; Georgios Vlasakakis; Nandita Biswas; Felix Calderon; Oscar Della Pasqua; Anna Gine-March; Zaida Herrador; Alfonso Mendoza-Losana; Gabriel Díez; Israel Cruz; Santiago Ramón-García
Journal:  Trials       Date:  2022-07-08       Impact factor: 2.728

Review 4.  Pharmacologic management of Mycobacterium ulcerans infection.

Authors:  Tjip S Van Der Werf; Yves T Barogui; Paul J Converse; Richard O Phillips; Ymkje Stienstra
Journal:  Expert Rev Clin Pharmacol       Date:  2020-04-20       Impact factor: 4.108

Review 5.  Buruli Ulcer: a Review of the Current Knowledge.

Authors:  Rie R Yotsu; Koichi Suzuki; Rachel E Simmonds; Roger Bedimo; Anthony Ablordey; Dorothy Yeboah-Manu; Richard Phillips; Kingsley Asiedu
Journal:  Curr Trop Med Rep       Date:  2018-09-28

6.  The paediatric participation scale measuring participation restrictions among former Buruli Ulcer patients under the age of 15 in Ghana and Benin: Development and first validation results.

Authors:  Dorien T Beeres; Jacolien Horstman; Pierre van der Tak; Richard O Phillips; Kabiru M Abass; Tjip van der Werf; Roch C Johnson; Ghislain E Sopoh; Janine de Zeeuw; Pieter U Dijkstra; Yves T Barogui; Ymkje Stienstra
Journal:  PLoS Negl Trop Dis       Date:  2019-03-14

7.  Transcriptional adaptation of Mycobacterium ulcerans in an original mouse model: New insights into the regulation of mycolactone.

Authors:  Marie Robbe-Saule; Mélanie Foulon; Isabelle Poncin; Lucille Esnault; Hugo Varet; Rachel Legendre; Alban Besnard; Anna E Grzegorzewicz; Mary Jackson; Stéphane Canaan; Laurent Marsollier; Estelle Marion
Journal:  Virulence       Date:  2021-12       Impact factor: 5.882

8.  Triple oral beta-lactam containing therapy for Buruli ulcer treatment shortening.

Authors:  María Pilar Arenaz-Callao; Rubén González Del Río; Ainhoa Lucía Quintana; Charles J Thompson; Alfonso Mendoza-Losana; Santiago Ramón-García
Journal:  PLoS Negl Trop Dis       Date:  2019-01-28

9.  Rifampicin and clarithromycin (extended release) versus rifampicin and streptomycin for limited Buruli ulcer lesions: a randomised, open-label, non-inferiority phase 3 trial.

Authors:  Richard O Phillips; Jérôme Robert; Kabiru Mohamed Abass; William Thompson; Fred Stephen Sarfo; Tuah Wilson; Godfred Sarpong; Thierry Gateau; Annick Chauty; Raymond Omollo; Michael Ochieng Otieno; Thaddaeus W Egondi; Edwin O Ampadu; Didier Agossadou; Estelle Marion; Line Ganlonon; Mark Wansbrough-Jones; Jacques Grosset; John M Macdonald; Terry Treadwell; Paul Saunderson; Albert Paintsil; Linda Lehman; Michael Frimpong; Nanaa Francisca Sarpong; Raoul Saizonou; Alexandre Tiendrebeogo; Sally-Ann Ohene; Ymkje Stienstra; Kingsley B Asiedu; Tjip S van der Werf
Journal:  Lancet       Date:  2020-03-12       Impact factor: 79.321

10.  Buruli ulcer treatment: Rate of surgical intervention differs highly between treatment centers in West Africa.

Authors:  Anita C Wadagni; Jonathan Steinhorst; Yves T Barogui; P M Catraye; Ronald Gnimavo; Kabiru M Abass; George Amofa; Michael Frimpong; Francisca N Sarpong; Tjip S van der Werf; Richard Phillips; Ghislain E Sopoh; Christian R Johnson; Ymkje Stienstra
Journal:  PLoS Negl Trop Dis       Date:  2019-10-28
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.